Dallas private equity firm Ancor Capital Partners has acquired a company in a growing niche of the health care industry that finds itself at the center of the fight over soaring pharmaceutical costs.
And a recent plan released by the Trump administration earlier this year to lower drug prices may give the investment an even bigger boost.
“As drug costs continue to increase, there is an increasing burden on pharmaceutical companies to justify pricing, and decision makers expect increasingly sophisticated…
